Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Ford Motor Company (F) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Ford Motor Company — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Ford Motor Company trades at $13.49 (market cap $54.03B). The key difference: Ford Motor Company is far larger — about 12× ACADIA Pharmaceuticals Inc.'s market cap, and Ford Motor Company pays a 4.42% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | F | |
|---|---|---|
Market Cap | $4.49B | $54.03B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $17.44 |
52-Week Low | $20.06 | $10.82 |
Enterprise Value | $3.69B | $183.06B |
Dividend Yield | — | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Ford Motor Company (F) trades at $13.57, up 1.65% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative net income margin and ROE. Recent developments include a strategic semiconductor supply agreement with Micron and vehicle recalls affecting over 110,000 Mustang models. Operating cash flow remains robust at $21.28 billion for 2025, though net income turned negative at -$8.18 billion.
Ford presents a value opportunity with attractive valuation ratios (P/E 11.84, P/S 0.29) but faces significant execution risks. The stock trades below analyst consensus target of $15.00, offering potential upside, though recent sales declines and profitability concerns warrant caution. Key catalysts include EV strategy execution and truck demand strength, while risks include competitive pressures and operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →
